Related Experiment Videos
Differential SP220K expression in renal carcinoma and oncocytoma cells
S Thaon1, C Ferrero, P Auberger
1Laboratoire de Biochimie, Faculte de Medecine, Nice, France.
Abstract:
SP220K is a newly described serine proteinase which displays guanidinobenzoatase activity in its inactive form and gelatinolytic activity in its active form. SP220K expression was studied in 20 renal clear-cell carcinomas and in a series of renal oncocytomas, a rare benign tumor derived from the kidney tubule epithelium. We provide evidence that SP220K expression, as assessed by guanidinobenzoatase activity, gelatin zymography and Western blot immunodetection, was increased markedly in cancer basolateral membranes compared to kidney cortex controls, whereas no signal was detectable in basolateral membranes from the 5 renal oncocytomas studied. Cytoplasms of carcinoma cells were immunodetected consistently, whereas no expression was seen in oncocytic cells from any of the oncocytomas studied (12/12). Endothelial cells were immunodetected in all 3 tissue types. Our data favor a potential mechanistic relationship between expression of the matrix proteinase SP220K and invasive phenotype in kidney epithelium proliferative processes.
Insights
This study investigated SP220K, a serine proteinase, in kidney cancers and benign tumors. SP220K was significantly elevated in renal clear-cell carcinomas, suggesting a role in cancer progression.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- SP220K is a novel serine proteinase with distinct enzymatic activities in its inactive and active forms.
- Renal clear-cell carcinoma is a common kidney cancer, while renal oncocytoma is a rare benign kidney tumor.
Purpose of the Study:
- To investigate the expression and localization of SP220K in renal clear-cell carcinomas and renal oncocytomas.
- To explore the potential relationship between SP220K expression and the invasive phenotype of kidney tumors.
Main Methods:
- Enzyme activity assays (guanidinobenzoatase activity).
- Gelatin zymography to assess gelatinolytic activity.
- Western blot immunodetection for SP220K protein.
- Immunohistochemical analysis of tissue samples.
Main Results:
- SP220K expression, indicated by guanidinobenzoatase activity and protein levels, was markedly increased in the basolateral membranes of renal clear-cell carcinomas compared to normal kidney cortex.
- No detectable SP220K signal was found in the basolateral membranes of renal oncocytomas.
- SP220K was consistently detected in the cytoplasm of carcinoma cells but not in oncocytic cells of oncocytomas.
- Endothelial cells showed SP220K expression across all tissue types.
Conclusions:
- SP220K expression is significantly upregulated in renal clear-cell carcinomas, distinguishing them from benign renal oncocytomas.
- The findings suggest a potential mechanistic link between SP220K expression and the invasive characteristics of kidney epithelial cells in proliferative processes.